Adagene Inc. announced a partnership with ConjugateBio Inc. on July 8, 2025, to develop novel antibody-drug conjugates (ADCs). Under the terms of the agreement, Adagene will provide a proprietary antibody for use in ConjugateBio's bispecific ADC development programs. This collaboration aims to combine Adagene's antibody discovery capabilities with ConjugateBio's expertise in streamlining ADC development.
Adagene is set to receive an undisclosed upfront payment, along with potential milestone and royalty payments from this partnership. The company will retain all non-ADC rights to the partnered antibody. This strategic move positions Adagene to tap into the rapidly growing ADC market, which is projected to exceed $30 billion by 2030.
The partnership validates Adagene's differentiated antibody discovery capabilities, as highlighted by ConjugateBio's CEO, Kum Yoo. This collaboration is expected to advance the ADC landscape by developing novel, potent, and safe antibody-drug conjugates, leveraging Adagene's expertise in creating well-tolerated and efficacious molecules.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.